Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × HR+ Breast Cancer × Fulvestrant × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Neoplasms 3 Neoplasm Metastasis 2 Multiple Endocrine Neoplasia Type 1 1 HR+ Breast Cancer 1 Breast Neoplasm Female 1 Breast Diseases 1 Breast Cancer Organoids 1

Interventions

sintilimab 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06734533 2024-12-16

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Hunan Cancer Hospital

HR+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡